# A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.

> **NCT06928363** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Novatim Immune Therapeutics (Zhejiang) Co., Ltd.** · enrollment: 212 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** KY-0301

## Key facts

- **NCT ID:** NCT06928363
- **Lead sponsor:** Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-11-12
- **Final completion:** 2027-12-15
- **Target enrollment:** 212 (ESTIMATED)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06928363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06928363, "A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06928363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*